Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid
Eli Lilly is licensing Sangamo Therapeutics’ AAV capsid for an undisclosed CNS disease target, and the $18 million upfront fee should give the beleaguered biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.